CD40 and breast carcinoma: A clinical study of CDX-1140, a CD40 agonist, for use as a monotherapy or in combination with the anti-PD-1 mAB, pembrolizumab, has been initiated in patients with advanced malignancies, including breast cancer (ClinicalTrials.gov Identifier: NCT03329950).